Engineering better chimeric antigen receptor T cells.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• CD19-targeted CAR T cells therapy is effective against B cell malignancies.
• Relapse, often antigen-positive, is a significant challenge linked to poor CAR T cells persistence.

Purpose of the Study:

• To review factors and mechanisms influencing CAR T cells in vivo persistence.
• To identify strategies to overcome limitations in CAR T cells therapy.

Main Methods:

• Literature review of factors affecting CAR T cells persistence.
• Analysis of CAR constructs, activation signaling, in vitro culture, epigenetics, tumor microenvironment, and T cell subsets.
• Focus on CAR T cells differentiation and exhaustion as central mechanisms.

Main Results:

• CAR T cells persistence is influenced by CAR design, activation, culture methods, epigenetics, tumor environment, and T cell subsets.
• Cell differentiation and exhaustion are key determinants of CAR T cells in vivo persistence.
• Various strategies to enhance CAR T cells persistence are discussed.

Conclusions:

• Understanding factors affecting CAR T cells persistence is critical for improving therapeutic efficacy.
• Targeting CAR T cells differentiation and exhaustion offers promising avenues for overcoming treatment resistance.
• Further research into optimizing CAR T cells is essential for long-term patient benefit.